An Australian medical cannabis company has launched its hemp based CBD teas – but you won’t be able to buy them in Australia.
Just over a year ago we mentioned Australia’s Creso Pharma Limited (ASX:CPH) announced its hemp teas should be available in international markets in the third quarter of last year.
While a bit behind the original schedule, the teas are now available in Switzerland. There are three products, now in their second generation:
- cannaQIX tea: developed to help manage stress – CBD, vitamins and zinc.
- cannaQIX NITE: as the name suggests, to support better sleep. Contains CBD and lemon balm.
- cannaQIX Immunity: CBD, vitamins, zinc, elderberry and ginger to “optimise well-being”.
The latter is a new product, not in the originally announced line-up.
All three teas contain 5-10 mg of CBD (assumed: single serve dose) – so it’s a very low dose. The teas can be mixed with hot or cold water.
“We are proud to have completed the finalisation of this ground breaking technology for our new CBD tea products, which opens a number of new and globally applicable opportunities for Creso Pharma,” said Commercial & Development Director Dr Gian Trepp.
But it’s unlikely one of those opportunities is Australia, unless Creso is shooting for a Schedule 3 listing as a medicine (or laws change).
However, the company is eyeing markets including Germany, following a German Federal Court of Justice decision declaring previous charges against hemp tea sellers invalid. The company is also looking to distribution of its hemp tea products in other European countries.
Creso is leveraging the established cannaQix brand with its teas, which is a nutraceutical line of products also including lozenges. Another new product on the boards is cannaQIX oral care, a lozenge product “supporting the reduction of stress and mouth hygiene”. The lozenges will contain 10 or 25mg of CBD, peppermint and sage essential oils.
In addition to products designed for humans, Creso Pharma produces feed supplements for animals under the “anibidiol” brand.
Beyond hemp, the company is also looking to dabble in psychedelic treatments – specifically compounds in botanical psilocybin; better known as “magic mushrooms”. This would occur through the planned acquisition of Canadian company Halucenex Life Sciences Inc.
